A PHASE 1b STUDY OF ZN-c3 IN COMBINATION WITH CHEMOTHERAPY OR BEVACIZUMAB IN SUBJECTS WITH OVARIAN, PERITONEAL, OR FALLOPIAN TUBE CANCER

This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability,
preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3 in
combination with other drugs.

Inclusion Criteria:

- Provision of written informed consent prior to initiation of any study-related
procedures that are not considered standard of care.

- Females ≥ 18 years of age or the minimum legal adult age (whichever is greater) at the
time of informed consent.

- ECOG performance status ≤ 2.

- Histologically or cytologically confirmed high-grade serous epithelial ovarian
carcinoma, fallopian tube, or peritoneal carcinoma.

- Subjects must have received 1 or 2 prior therapeutic regimens/lines of therapy in the
advanced or metastatic setting.

- The disease must be platinum-resistant, i.e., the Platinum-Free Interval (PFI) must
have been < 6 months. Platinum refractory disease, i.e., PD during first-line
platinum-based therapy is allowed.

- Measurable disease per RECIST version 1.1.

- Adequate hematologic and organ function as defined by the following criteria:

1. ANC ≥ 1.5 × 10^9/L; excluding measurements obtained within 7 days after daily
administration of filgrastim/sargramostim or within 3 weeks after administration
of pegfilgrastim.

2. Platelet count ≥ 100 × 10^9/L; excluding measurements obtained within 3 days
after transfusion of platelets or within 3 weeks after administration of platelet
growth factors.

3. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 × upper
limit of normal (ULN). If liver function abnormalities are due to underlying
liver metastases, AST and ALT ≤ 5 x ULN.

4. Total serum bilirubin ≤ 1.5 × ULN or ≤ 3 × ULN in the case of Gilbert's disease.

5. Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 60 mL/min.

- Female subjects of childbearing potential must have a negative serum beta human
chorionic gonadotropin (β-hCG) test and agree to use an effective method of
contraception per institutional standard.

- Left ventricular ejection fraction (LVEF) ≥ 50% or within normal limits of the
institution (only for subjects treated with PLD).

Exclusion Criteria:

- Histology of abdominal adenocarcinoma of unknown origin or diagnosis of a borderline
ovarian tumor.

- Any of the following treatment interventions within the specified time frame prior to
Cycle 1 Day 1:

1. Major surgery within 28 days.

2. Radiation therapy within 21 days.

3. Autologous or allogeneic stem cell transplant within 3 months.

4. Inability to discontinue treatment for 5 half-lives or 14 days (whichever is
longer) prior to Cycle 1 Day 1 with prescription or non-prescription drugs, or to
discontinue consumption of food and herbal supplements, that are:

- strong and moderate CYP3A inhibitors

- strong and moderate CYP3A inducers

- P-gp inhibitors

- A serious illness or medical condition(s) including, but not limited to, the
following:

1. Brain metastases that require immediate treatment or are clinically or
radiographically unstable.

2. Leptomeningeal disease that requires or is anticipated to require immediate
treatment.

3. Myocardial impairment of any cause.

4. Significant gastrointestinal abnormalities.

5. Active or uncontrolled infection.

6. Any evidence of small bowel obstruction as determined by air/fluid levels on
computed tomography (CT) scan, recent hospitalization for small bowel obstruction
within 3 months prior to Cycle 1 Day 1, or recurrent paracentesis or
thoracentesis within 6 weeks prior to Cycle 1 Day 1.

- Unresolved toxicity of Grade > 1 attributed to any prior therapies (excluding Grade 2
neuropathy, alopecia or skin pigmentation).

- Pregnant or lactating females (including the cessation of lactation) or females of
childbearing potential who have a positive serum pregnancy test within 14 days prior
to Cycle 1 Day 1.

- Subjects with active (uncontrolled, metastatic) second malignancies or requiring
therapy.

- 12-lead ECG demonstrating a corrected QT interval using Fridericia's formula (QTcF) of
> 480 msec, except for subjects with atrioventricular pacemakers or other conditions
(e.g., right bundle branch block) that render the QT measurement invalid.

- History or current evidence of congenital long QT syndrome.